Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2236 to 2250 of 7710 results

  1. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development [GID-TA11504] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

    Awaiting development [GID-TA10757] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke

    Diagnostics guidance
    Last updated
    2 May 2024
    View recommendations

    Sections for DG57

  4. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development [GID-TA11470] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

    Medical technologies guidance
    Last updated
    8 October 2019
    View recommendations

    Sections for MTG12

  9. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    Awaiting development [GID-TA11468] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    Awaiting development [GID-TA11278] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development [GID-IPG10409] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  15. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

    Medical technologies guidance
    Last updated
    1 March 2015
    View recommendations

    Sections for MTG22